(Q52068509)

21 April 2018

title

Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. (English)

1 reference

21 April 2018

6

J V Haxby

1 reference

21 April 2018

author name string

T T Soncrant

1

1 reference

21 April 2018

K C Raffaele

2

1 reference

21 April 2018

S Asthana

3

1 reference

21 April 2018

A Berardi

4

1 reference

21 April 2018

P P Morris

5

1 reference

21 April 2018

publication date

1 January 1993

1 reference

21 April 2018

published in

Psychopharmacology

1 reference

21 April 2018

volume

112

1 reference

21 April 2018

issue

4

1 reference

21 April 2018

page(s)

421-427

1 reference

21 April 2018

https://scigraph.springernature.com/pub.10.1007/bf02244889

exact match

0 references

cites work

Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Induction of depression with oxotremorine in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

The effect of long-term physostigmine administration in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Long-term administration of oral physostigmine in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Multiple-dose arecoline infusions in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02244889

Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase

21 January 2018

1 reference

12 December 2020

A geriatric rating scale empirically derived from three rating scales for geriatric behaviour

1 reference

12 December 2020

Cholinergic receptor interactions and their effects on long-term memory processing.

1 reference

12 December 2020

Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains.

1 reference

12 December 2020

An automatic reaction control chemical ionization technique in ion trap detector for quantitative plasma profding of arecoline in treated alzheimer patients.

1 reference

12 December 2020

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia

1 reference

12 December 2020

Tacrine in Alzheimer's disease

1 reference

12 December 2020

Cholinomimetic treatment fails to improve memory disorders.

1 reference

12 December 2020

Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT)

1 reference

12 December 2020

Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.

1 reference

12 December 2020

Oral physostigmine and lecithin improve memory in Alzheimer disease

1 reference

12 December 2020

Latent sensory aphasia in hemisphere-damaged patients: an experimental study with the Token Test.

1 reference

12 December 2020

Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study

1 reference

12 December 2020

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

1 reference

12 December 2020

Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.

1 reference

12 December 2020

Memory deficits in aged cebus monkeys and facilitation with central cholinomimetics

1 reference

12 December 2020

Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: modification by cholinergic drugs

1 reference

12 December 2020

1 reference

12 December 2020

Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type

1 reference

12 December 2020

Episodic and semantic memory: a comparison of amnesic and demented patients

1 reference

12 December 2020

Physostigmine effects in Alzheimer's disease: relationship to dementia severity.

1 reference

12 December 2020

Effects of physostigmine and lecithin on memory in Alzheimer disease

1 reference

12 December 2020

Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats

1 reference

12 December 2020

Relative potencies of agonists and differential sensitivity to N-ethylmaleimide on muscarinic autoreceptors and postsynaptic receptors in rat hippocampus

1 reference

12 December 2020

RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.

1 reference

12 December 2020

No response to high-dose muscarinic agonist therapy in Alzheimer's disease

1 reference

12 December 2020

Cellular ageing: selective vulnerability of cholinergic neurones in human brain.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02244889

1 reference

21 April 2018

1 reference

21 April 2018